Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney Disease
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorCantonal Hospital Graubuenden
About this trial
This study aims to better understand electrolyte handling in patients with autosomal dominant polycystic kidney disease treated with the SGLT2 inhibitor Empagliflozin.
Patients will be randomized into two groups and take Empagliflozin or a Placebo for 2 weeks with a wash-out period of 2 weeks. The primary outcome is tubular handling of the divalent ions calcium, phosphate and magnesium. Secondary outcomes include diuresis, safety and tolerability.
Eligibility criteria
Qualifiers
- Patients 18-75 years old with ADPKD, defined according to international diagnostic and classification criteria14, treated at Cantonal Hospital Graubünden (KSGR) and the University Hospital Zürich (USZ) independent of baseline treatment with the vasopressin receptor antagonist Tolvaptan
Informed consent as documented by signature
Disqualifiers
- renal replacement therapy or kidney allograft recipient
chronic kidney disease CKD KDIGO Stage G4 (eGFR under 30ml/min/1.73m2)
patients younger 18 years of age
Diabetes mellitus type 1
Trial design
Treatments tested in this trial
- Empagliflozin
- Placebo
Treatment groups
40 Participants
are divided into 2 treatment groupsSponsors and collaborators
Cantonal Hospital Graubuenden
Lead sponsor
University of Zurich
Collaborator
Source ClinicalTrials.gov